Literature DB >> 22127194

Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study.

Rudolf Uher1, Ole Mors, Marcella Rietschel, Aleksandra Rajewska-Rager, Ana Petrovic, Astrid Zobel, Neven Henigsberg, Julien Mendlewicz, Katherine J Aitchison, Anne Farmer, Peter McGuffin.   

Abstract

OBJECTIVE: The timing and rate of improvement after the initiation of an antidepressant has implications for establishing the mechanism of antidepressant action and for answering the clinically relevant question of how long an appropriate trial of antidepressant medication should be. We explore the individual trajectories of relative change in depression severity to establish what proportion of individuals experience early and late onset of improvement.
METHOD: Longitudinal latent class analysis was applied in a secondary analysis of data obtained from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. In the GENDEP trial, conducted in 9 European academic psychiatry centers from July 2004 to June 2008, 811 treatment-seeking adult subjects with DSM-IV major depression received escitalopram or nortriptyline for 12 weeks. Montgomery-Asberg Depression Rating Scale measurements were taken weekly. The secondary analysis reported in this article was conducted in 2010.
RESULTS: A model with 9 latent classes provided a good description of the individual trajectories of symptom change over time. These classes included 3 nonresponder classes, 3 classes with varying degrees of improvement concentrated in the first 3 weeks (early improvement), and 3 classes with varying degrees of improvement that was more prominent in the second 3 weeks than in the first 3 weeks (delayed improvement). More than half of the subjects who eventually reached remission showed a pattern of delayed improvement, and their eventual outcome could not be predicted from early time points. Early marked response occurred more frequently in subjects treated with nortriptyline than in those treated with escitalopram (12.9% vs 7.5%, χ² = 6.29, P = .01). Delayed complete remission occurred more frequently in subjects treated with escitalopram than in those treated with nortriptyline (13.6% vs 6.1%, χ² = 11.52, P = .0007).
CONCLUSIONS: Both early and delayed improvement are common. Although early changes are maintained, the eventual outcome of 12-week antidepressant treatment can be accurately predicted only after 8 weeks. TRIAL REGISTRATION: http://www.controlled-trials.com Identifier: ISRCTN03693000. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22127194     DOI: 10.4088/JCP.10m06419

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  37 in total

Review 1.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

2.  Systems genetics analysis of pharmacogenomics variation during antidepressant treatment.

Authors:  M B Madsen; L J A Kogelman; H N Kadarmideen; H B Rasmussen
Journal:  Pharmacogenomics J       Date:  2016-10-18       Impact factor: 3.550

3.  Trajectories of change in anxiety severity and impairment during and after treatment with evidence-based treatment for multiple anxiety disorders in primary care.

Authors:  Jutta M Joesch; Daniela Golinelli; Cathy D Sherbourne; Greer Sullivan; Murray B Stein; Michelle G Craske; Peter P Roy-Byrne
Journal:  Depress Anxiety       Date:  2013-06-25       Impact factor: 6.505

4.  The effectiveness of prefrontal theta cordance and early reduction of depressive symptoms in the prediction of antidepressant treatment outcome in patients with resistant depression: analysis of naturalistic data.

Authors:  Martin Bares; Tomas Novak; Miloslav Kopecek; Martin Brunovsky; Pavla Stopkova; Cyril Höschl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-05-22       Impact factor: 5.270

5.  Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms.

Authors:  R Uher; R H Perlis; N Henigsberg; A Zobel; M Rietschel; O Mors; J Hauser; M Z Dernovsek; D Souery; M Bajs; W Maier; K J Aitchison; A Farmer; P McGuffin
Journal:  Psychol Med       Date:  2011-09-20       Impact factor: 7.723

6.  Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial.

Authors:  Kimberly A Yonkers; Susan G Kornstein; Ralitza Gueorguieva; Brian Merry; Kari Van Steenburgh; Margaret Altemus
Journal:  JAMA Psychiatry       Date:  2015-10       Impact factor: 21.596

7.  Genetic moderation of child maltreatment effects on depression and internalizing symptoms by serotonin transporter linked polymorphic region (5-HTTLPR), brain-derived neurotrophic factor (BDNF), norepinephrine transporter (NET), and corticotropin releasing hormone receptor 1 (CRHR1) genes in African American children.

Authors:  Dante Cicchetti; Fred A Rogosch
Journal:  Dev Psychopathol       Date:  2014-11

8.  Antidepressant Response Trajectories and Associated Clinical Prognostic Factors Among Older Adults.

Authors:  Stephen F Smagula; Meryl A Butters; Stewart J Anderson; Eric J Lenze; Mary Amanda Dew; Benoit H Mulsant; Francis E Lotrich; Howard Aizenstein; Charles F Reynolds
Journal:  JAMA Psychiatry       Date:  2015-10       Impact factor: 21.596

9.  Piperine Augments the Protective Effect of Curcumin Against Lipopolysaccharide-Induced Neurobehavioral and Neurochemical Deficits in Mice.

Authors:  Ashok Jangra; Mohit Kwatra; Tavleen Singh; Rajat Pant; Pawan Kushwah; Yogita Sharma; Babita Saroha; Ashok Kumar Datusalia; Babul Kumar Bezbaruah
Journal:  Inflammation       Date:  2016-06       Impact factor: 4.092

10.  2-Phenyl-3-(phenylselanyl)benzofuran elicits acute antidepressant-like action in male Swiss mice mediated by modulation of the dopaminergic system and reveals therapeutic efficacy in both sexes.

Authors:  Taís da Silva Teixeira Rech; Amália Gonçalves Alves; Dianer Nornberg Strelow; Letícia Devantier Krüger; Luiz Roberto Carraro Júnior; José Sebastião Dos Santos Neto; Antonio Luiz Braga; César Augusto Brüning; Cristiani Folharini Bortolatto
Journal:  Psychopharmacology (Berl)       Date:  2021-07-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.